PSMA-targeting imaging agents
US9713649B2 · kind B2 · utility
2Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 26, 2015 |
| Grant date | Jul 25, 2017 |
| Priority date | — |
| Expiry date | Jan 26, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K51/0497
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A PSMA-specific imaging agent comprising a compound according to formula I:are described, wherein S1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.